Yidong Chen

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity

  Cancer Research · 2025-12-02

• Transformer and graph variational autoencoder to identify microenvironments: A deep learning protocol for spatial transcriptomics

  STAR Protocols · 2025-11-27 · 1 citations

• Supplementary Data from Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma

  2025-11-27

• Supplemental Table S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplemental Figure S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplemental Figure S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplemental Table S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplemental Table S3 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• Supplemental Figure S3 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

  2025-11-25

• EXTH-104. Dual Targeting of KDM1A/LSD1 and Endoplasmic Reticulum Stress Pathways as a Therapeutic Strategy in Glioblastoma

  Neuro-Oncology · 2025-11-01

• Ligand-receptor interactions induce and mediate regulatory functions of BATF3 ⁺ B cells

  Science Advances · 2025-10-08 · 1 citations

• Figure S4 from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01

• Supplementary Tables 1-4 from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01

• Figure S3 from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01

• Figure S1 from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01

• Figure S2 from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01

• SERHL regulates invasion and metastasis through KLF16-PLCB1/PRKCA signaling in gastric cancer cells

  Genes & Diseases · 2025-10-01

• Data from Targeting DDR2 for Treating Pancreatic Cancer

  2025-10-01